{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:14:09Z","timestamp":1778753649919,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to develop an effective model for predicting Hodgkin lymphoma (HL) prognosis as to assist clinicians in making optimal clinical decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study screened HL patients from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2021. Feature selection was performed using the Boruta algorithm. Four ML models were built based on the feature selection algorithm. The area under the curve (AUC), decision curve analysis, and Brier score were employed to evaluate the reliability of the four ML models. The feature importance was ranked through the Shapley Additive Explanation (SHAP). Based on the results of the SHAP plot, Kaplan\u2013Meier analysis was used to compare the survival probabilities among different groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 11,259 enrolled HL patients, 8,928 were alive and 2,331 had died. Primary site, year of diagnosis, B symptoms, surgery, marital status, Ann Arbor stage, radiation, SEER stage, chemotherapy, delay (diagnosis to treatment), age were associated with HL overall survival (OS). Of four ML models, the eXtreme Gradient Boosting (XGBoost) model exhibited superior predictive performance. For predicting 1-year OS, the net benefit of XGBoost, Cox proportional hazards (Coxph), and Random Survival Forest (RSF) models was significantly higher than that of the Light Gradient Boosting Machine (LightGBM) model, the treat-all model, and the treat-none model. Age, Ann Arbor stage, B symptoms, marital status, and radiation were the top five indicators in the feature importance ranking for HL OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The XGBoost had excellent predictive performance in the prognostic model, which further helps clinicians to select appropriate treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00277-026-06791-x","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:54:05Z","timestamp":1777517645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting survival of Hodgkin lymphoma using machine learning-an analysis based on the SEER database"],"prefix":"10.1007","volume":"105","author":[{"given":"Xinzhen","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"10","key":"6791_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.clml.2023.06.006","volume":"23","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Ansell SM (2023) SOHO state of the art updates and next questions | From biology to therapy: progress in Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 23(10):705\u2013713","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"6791_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1182\/blood-2021-147354","volume":"138","author":"DR Flora","year":"2021","unstructured":"Flora DR, Parsons SK, Liu N, Yu KS, Holmes K, Flores C et al (2021) Classical Hodgkin lymphoma; Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT)-a cross-sectional survey of patients with stage III or IV classical Hodgkin lymphoma compared by age. Blood 138(Supplement 1):1966","journal-title":"Blood"},{"key":"6791_CR3","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"issue":"3","key":"6791_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433502","volume":"44","author":"C Burton","year":"2024","unstructured":"Burton C, Allen P, Herrera AF (2024) Paradigm shifts in Hodgkin lymphoma treatment: from frontline therapies to relapsed disease. Am Soc Clin Oncol Educ Book 44(3):e433502","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"6791_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153745","author":"H Vellemans","year":"2021","unstructured":"Vellemans H, Andr\u00e9 MPE (2021) Review of treatment options for the management of advanced stage Hodgkin lymphoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13153745","journal-title":"Cancers (Basel)"},{"issue":"54","key":"6791_CR6","doi-asserted-by":"publisher","first-page":"92978","DOI":"10.18632\/oncotarget.21722","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang J, Zeng H, Zhou XH, Zhou HB (2017) Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study. Oncotarget 8(54):92978\u201392988","journal-title":"Oncotarget"},{"key":"6791_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215390","author":"AM Follows","year":"2022","unstructured":"Follows AM, Santarsieri A (2022) Minimising the toxicities of first line Hodgkin lymphoma treatment in the modern era. Cancers. https:\/\/doi.org\/10.3390\/cancers14215390","journal-title":"Cancers"},{"issue":"1","key":"6791_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01600-7","volume":"8","author":"W Liu","year":"2023","unstructured":"Liu W, Lin N, Feng X, Xie Y, You C, Zhou X et al (2023) Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Signal Transduct Target Ther 8(1):356","journal-title":"Signal Transduct Target Ther"},{"key":"6791_CR9","doi-asserted-by":"crossref","unstructured":"Fehr M, Lang N, Rubio L, G\u00fcsewell S, Templeton AJ, Aeppli S, et al (2021) Prognostic factors in elderly patients with classical hodgkin lymphoma - a joint analysis of two clinical databases.\u00a0Hematol Oncol 39(S2):201","DOI":"10.1002\/hon.113_2880"},{"issue":"11","key":"6791_CR10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00247-019-04529-8","volume":"49","author":"KM McCarten","year":"2019","unstructured":"McCarten KM, Nadel HR, Shulkin BL, Cho SY (2019) Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol 49(11):1545\u20131564","journal-title":"Pediatr Radiol"},{"key":"6791_CR11","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos TP, Liaskas A, Rizzuto G, Symeonidis A, Palma M, Angelopoulou MK, et al. (2023) Treatment strategies and prognostic factors for the outcome of patients with hodgkin lymphoma experiencing very late relapses after chemotherapy \u00b1 radiotherapy. 41(S2):677-.","DOI":"10.1002\/hon.3165_527"},{"issue":"3","key":"6791_CR12","first-page":"108","volume":"16","author":"S Makita","year":"2020","unstructured":"Makita S, Maruyama D, Maeshima AM, Taniguchi H, Yuda S, Toyoda K et al (2020) A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma 16(3):108\u2013114","journal-title":"A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma"},{"issue":"3","key":"6791_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10428194.2022.2157214","volume":"64","author":"K Simba","year":"2023","unstructured":"Simba K, Mohamed Z, Opie JJ, Andera LF, Brown K, Oosthuizen J et al (2023) The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma. Leuk Lymphoma 64(3):613\u2013620","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6791_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/tri.13818","volume":"34","author":"A Ferrarese","year":"2021","unstructured":"Ferrarese A, Sartori G, Orr\u00f9 G, Frigo AC, Pelizzaro F, Burra P et al (2021) Machine learning in liver transplantation: a tool for some unsolved questions? Transplant Int 34(3):398\u2013411","journal-title":"Transplant Int"},{"issue":"1","key":"6791_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84556-4","volume":"11","author":"X Pu","year":"2021","unstructured":"Pu X, Deng D, Chu C, Zhou T, Liu J (2021) High-dimensional hepatopath data analysis by machine learning for predicting HBV-related fibrosis. Sci Rep 11(1):5081","journal-title":"Sci Rep"},{"issue":"6","key":"6791_CR16","first-page":"3035","volume":"37","author":"S Master","year":"2017","unstructured":"Master S, Koshy N, Wilkinson B, Rosen L, Mills G, Mansour R et al (2017) Effect of radiation therapy on survival in Hodgkin\u2019s lymphoma: a SEER data analysis. Anticancer Res 37(6):3035\u20133043","journal-title":"Anticancer Res"},{"key":"6791_CR17","doi-asserted-by":"publisher","first-page":"S350","DOI":"10.1016\/S2152-2650(22)01484-7","volume":"22","author":"H Shah","year":"2022","unstructured":"Shah H, Seongho K, Halwani A, Hyejeong J (2022) HL-526 improved survival of elderly patients with classical Hodgkin lymphoma (cHL) in the modern era - a SEER-registry analysis. Clin Lymphoma Myeloma Leuk 22:S350\u2013S351","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"6791_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055524","volume":"12","author":"X Liang","year":"2022","unstructured":"Liang X, Zhang M, Zhang Z, Tan S, Li Y, Zhong Y et al (2022) Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin\u2019s lymphoma: an observational study using SEER population-based data. BMJ Open 12(6):e055524","journal-title":"BMJ Open"},{"issue":"5","key":"6791_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjh.18564","volume":"200","author":"H Shah","year":"2023","unstructured":"Shah H, Jang H, Kim S, Halwani AS (2023) A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br J Haematol 200(5):579\u2013586","journal-title":"Br J Haematol"},{"key":"6791_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae221","author":"A Zhao","year":"2025","unstructured":"Zhao A, Sun X, Cheng W, Yang Y, Xiang B, Niu T (2025) Epidemiology characteristics and clinical outcomes of composite Hodgkin lymphoma and diffuse large B-cell lymphoma using machine learning. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyae221","journal-title":"Oncologist"},{"key":"6791_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1628909","volume":"16","author":"X Liang","year":"2025","unstructured":"Liang X, Wang C, Tang Y, Xie X, Wu Y, Min H et al (2025) Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China. Front Immunol 16:1628909","journal-title":"Front Immunol"},{"issue":"1","key":"6791_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27402","volume":"66","author":"AS Fahy","year":"2019","unstructured":"Fahy AS, Kong I, Weitzman S, Dix D, Baruchel S, Gerstle JT (2019) A role for surgery in the treatment of relapsed Hodgkin lymphoma. Pediatr Blood Cancer 66(1):e27402","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"6791_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/su131810110","volume":"13","author":"H Ahmadpour","year":"2021","unstructured":"Ahmadpour H, Bazrafshan O, Rafiei-Sardooi E, Zamani H, Panagopoulos T (2021) Gully erosion susceptibility assessment in the Kondoran watershed using machine learning algorithms and the Boruta feature selection. Sustainability 13(18):10110","journal-title":"Sustainability"},{"key":"6791_CR24","doi-asserted-by":"crossref","unstructured":"Boukrouh I, Tayalati F, Azmani A (2024) Feature selection and classification performance: a multi-dataset comparative analysis using boruta algorithm and random forest. Proceedings of the International Conference on Computer, Information and System Security (CIST) CIST 174","DOI":"10.11159\/cist24.174"},{"key":"6791_CR25","unstructured":"Ampomah O-A, Agyemang E, Acheampong K, Agyekum LJapa (2025) Enhancing credit default prediction using boruta feature selection and DBSCAN algorithm with different resampling techniques. arXiv preprint"},{"issue":"9","key":"6791_CR26","doi-asserted-by":"publisher","first-page":"e0000299","DOI":"10.1371\/journal.pdig.0000299","volume":"3","author":"C Lokker","year":"2024","unstructured":"Lokker C, Abdelkader W, Bagheri E, Parrish R, Cotoi C, Navarro T et al (2024) Boosting efficiency in a clinical literature surveillance system with LightGBM. PLOS digital health 3(9):e0000299","journal-title":"PLOS digital health"},{"key":"6791_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/27541231241249866","volume":"3","author":"L Yang","year":"2024","unstructured":"Yang L, Yang H, Cui J, Zhao Y, Gao F (2024) Non-linear and synergistic effects of built environment factors on older adults\u2019 walking behavior: an analysis integrating LightGBM and SHAP. Transactions in Urban Data Sci Technol 3:46\u201360","journal-title":"Transactions in Urban Data Sci Technol"},{"key":"6791_CR28","first-page":"104417","volume":"194","author":"S Xie","year":"2025","unstructured":"Xie S, Liao F (2025) Nonlinear effects of changes in the built environment and life events on mode choice: a longitudinal analysis. Transportation Res Part A: Policy and Practice 194:104417","journal-title":"Transportation Res Part A: Policy and Practice"},{"issue":"6","key":"6791_CR29","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.21037\/jgo-22-1238","volume":"13","author":"Q Xu","year":"2022","unstructured":"Xu Q, Lu X (2022) Development and validation of an XGBoost model to predict 5-year survival in elderly patients with intrahepatic cholangiocarcinoma after surgery: a SEER-based study. J Gastrointest Oncol 13(6):3290\u20133299","journal-title":"J Gastrointest Oncol"},{"key":"6791_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/15501329221106935","volume":"18","author":"P Zhang","year":"2022","unstructured":"Zhang P, Jia Y, Shang Y (2022) Research and application of XGBoost in imbalanced data. Int J Distrib Sens Netw 18:155013292211069","journal-title":"Int J Distrib Sens Netw"},{"issue":"2","key":"6791_CR31","doi-asserted-by":"publisher","DOI":"10.34172\/jrhs.2021.47","volume":"21","author":"F Shahbazi","year":"2021","unstructured":"Shahbazi F, Karami M, Mirzaei M, Mohammadi Y (2021) Survival rates and prognostic factors in patients with Coronavirus disease 2019: a registry-based retrospective cohort study. J Res Health Sci 21(2):e00515","journal-title":"J Res Health Sci"},{"issue":"6","key":"6791_CR32","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/jcsm.13623","volume":"15","author":"Z Qin","year":"2024","unstructured":"Qin Z, Xu Y (2024) Comment on \u2018Change in Physical Activity and Its Association With Decline in Kidney Function: A UK Biobank-Based Cohort Study\u2019 by Liu et al. J Cachexia Sarcopenia Muscle 15(6):2883\u20132884","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6791_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.csda.2018.01.017","volume":"123","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhang B (2018) Semiparametric spatial model for interval-censored data with time-varying covariate effects. Comput Stat Data Anal 123:146\u2013156","journal-title":"Comput Stat Data Anal"},{"issue":"1","key":"6791_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66261-0","volume":"14","author":"B Zhao","year":"2024","unstructured":"Zhao B, Nguyen VK, Xu M, Colacino JA, Jolliet O (2024) Random survival forest for predicting the combined effects of multiple physiological risk factors on all-cause mortality. Sci Rep 14(1):15566","journal-title":"Sci Rep"},{"issue":"6","key":"6791_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/ajcp\/aqab076","volume":"156","author":"PD Simonson","year":"2021","unstructured":"Simonson PD, Wu Y, Wu D, Fromm JR, Lee AY (2021) De novo identification and visualization of important cell populations for classic Hodgkin lymphoma using flow cytometry and machine learning. Am J Clin Pathol 156(6):1092\u20131102","journal-title":"Am J Clin Pathol"},{"key":"6791_CR36","doi-asserted-by":"publisher","first-page":"9951","DOI":"10.2147\/IJGM.S341557","volume":"14","author":"Z Kuang","year":"2021","unstructured":"Kuang Z, Tu J, Li X (2021) Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma. International journal of general medicine 14:9951\u20139963","journal-title":"International journal of general medicine"},{"key":"6791_CR37","doi-asserted-by":"crossref","unstructured":"Rask Kragh J\u00f8rgensen R, Bergstr\u00f6m F, Eloranta S, Tang Severinsen M, Bj\u00f8ro Smeland K, Foss\u00e5 A, et al (2024) Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma. JCO clinical cancer informatics. 8:e2300255.","DOI":"10.1200\/CCI.23.00255"},{"issue":"3","key":"6791_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/biomedinformatics3030035","volume":"3","author":"H Wang","year":"2023","unstructured":"Wang H, Liu Z, Yang J, Sheng L, Chen D (2023) Using machine learning to expand the Ann Arbor staging system for Hodgkin and non-Hodgkin lymphoma. BioMedInformatics 3(3):514\u2013525","journal-title":"BioMedInformatics"},{"issue":"6","key":"6791_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70003","volume":"42","author":"M Picardi","year":"2024","unstructured":"Picardi M, Vincenzi A, Giordano C, Fazio LD, Pugliese N, Scarpa A et al (2024) Liposomal doxorubicin, vinblastine and dacarbazine plus consolidation radiotherapy of residual nodal masses for frontline treatment in older adults with advanced stage classic Hodgkin lymphoma: improved outcome in a multi-center real-life study. Hematol Oncol 42(6):e70003","journal-title":"Hematol Oncol"},{"key":"6791_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799948","volume":"11","author":"D Bhurani","year":"2021","unstructured":"Bhurani D, Nair R, Rajappa S, Rao SA, Sridharan N, Boya RR et al (2021) Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India. Front Oncol 11:799948","journal-title":"Front Oncol"},{"issue":"12","key":"6791_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101636","volume":"9","author":"JY Qian","year":"2024","unstructured":"Qian JY, Amin R, Ali H, Cao Y, Switchenko JM, Rashid AS et al (2024) Fifteen-year experience of a single institution: outcomes for early-stage Hodgkins lymphoma comparing chemotherapy alone versus combined modality therapy. Adv Radiat Oncol 9(12):101636","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"6791_CR42","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.clml.2020.08.015","volume":"21","author":"A Boil\u00e8ve","year":"2021","unstructured":"Boil\u00e8ve A, Grignano E, Bouscary D, Fourquet A, Deau-Fischer B, Kirova Y (2021) Relapsed, refractory, or advanced Hodgkin lymphoma: a single-center experience. Clin Lymphoma Myeloma Leuk 21(1):e27\u2013e31","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6791_CR43","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ijrobp.2019.06.445","volume":"105","author":"C Baues","year":"2019","unstructured":"Baues C, Goergen H, Fuchs M, Kobe C, Dietlein M, Rosenbrock J et al (2019) Consolidating involved field radiotherapy prevents early and local recurrences in early stage Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 105(1):S32\u2013S33","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6791_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2020.06.046","volume":"150","author":"K Nielsen","year":"2020","unstructured":"Nielsen K, Maraldo MV, Berthelsen AK, Loft A, de Nully BP, Vogelius IR et al (2020) Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome. Radiother Oncol 150:236\u2013244","journal-title":"Radiother Oncol"},{"issue":"5","key":"6791_CR45","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: preliminary results of a single-centre phase II study. Br J Haematol 198(5):847\u2013860","journal-title":"Br J Haematol"},{"issue":"5","key":"6791_CR46","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","volume":"107","author":"AM Evens","year":"2022","unstructured":"Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J et al (2022) Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica 107(5):1086\u20131094","journal-title":"Haematologica"},{"issue":"7","key":"6791_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","volume":"39","author":"L Pagano","year":"2025","unstructured":"Pagano L, Maschmeyer G, Lamoth F, Blennow O, Xhaard A, Spadea M et al (2025) Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European conference on infections in leukemia (ECIL). Leukemia 39(7):1547\u20131557","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06791-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:23:08Z","timestamp":1778750588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06791-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6791"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06791-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}